Moderna Stock Moves Lower Wednesday: What's Going On?

Moderna (NASDAQ: MRNA) stock is trading lower on Wednesday after a significant 170% surge in the past month. The decline follows major clinical breakthroughs, including a positive Phase 3 trial for an individualized mRNA cancer therapy and regulatory approvals for its flu and updated COVID-19 vaccines, alongside a $2.6 billion capital raise. However, broader macroeconomic headwinds and elevated Treasury yields are contributing to the selling pressure.